The Cost Effectiveness of Genetic Testing for CYP2C19 Variants to Guide Thienopyridine Treatment in Patients with Acute Coronary Syndromes: A New Zealand Evaluation

Author： Panattoni Laura   Brown Paul M.   >   Webster Mark   Gladding Patrick  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.30, Iss.11, 2012-11, pp. : 1067-1084

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Research Highlights: CYP2C19 genetic variants and clopidogrel responsiveness in acute coronary syndrome: are we ready for individualized therapy?

By Giusti Betti   Gori Anna Maria   Marcucci Rossella   Abbate Rosanna  

Pharmacogenomics, Vol. 10, Iss. 7, 2009-07 ,pp. : 1131-1133

Future Medicine

Access to resources Recommend Favorite

Genetic testing good to guide thienopyridine treatment

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 664, 2012-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Cost–effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia

By Sorich Michael J   Horowitz John D   Sorich Wassana   Wiese Michael D   Pekarsky Brita   Karnon Jonathan D  

Pharmacogenomics, Vol. 14, Iss. 16, 2013-12 ,pp. : 2013-2021

Future Medicine

Access to resources Recommend Favorite

Cost-effectiveness of ticagrelor in acute coronary syndromes

By Henriksson Martin   Janzon Magnus  

Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 13, Iss. 1, 2013-02 ,pp. : 9-18

Informa Healthcare

Access to resources Recommend Favorite

Cost Effectiveness of Anticoagulation in Acute Coronary Syndromes

By Latour-Pérez Jaime   de-Miguel-Balsa Eva  

PharmacoEconomics, Vol. 30, Iss. 4, 2012-04 ,pp. : 303-321

Adis International

Access to resources Recommend Favorite